Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

What’s Going On With Evolve Transition Infrastructure (SNMP) Stock Today?

Evolve Transition Infrastructure, LP (AMEX:SNMP) shares are moving higher on above-average trading volume on Tuesday. Here's a look at what's going on. What To Know:
byErica Kollmann
August 1, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Evolve Transition Infrastructure, LP (AMEX:SNMP) shares are moving higher on above-average trading volume on Tuesday. Here’s a look at what’s going on.

What To Know:

Shares of SNMP are up by 47% on very heavy trading volume. According to data from Benzinga Pro, more than 1.92 million shares have been traded, far exceeding the stock’s 100-day average of 43,996 shares. 

Evolve Transition announced last Wednesday that the NYSE Regulation had withdrawn its delisting determination, and the company’s common units commenced trading on the NYSE American on Monday.

Evolve Transition Infrastructure LP is focused on the acquisition and development of infrastructure of lower carbon energy sources and supply. The Company owns natural gas gathering systems, pipelines, and processing facilities in South Texas.

Related News: What’s Going On With ABVC BioPharma Stock?

SNMP Price Action: According to Benzinga Pro, shares of SNMP are trading 30.9% higher at $10.01 at the time of publication.

Image: janjf93 from Pixabay

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Nasdaq, S&P 500 Futures Build On Inflation-Data Momentum But Analyst Warn ‘Desperately Craved’ Rally May Not Sustain — Key Stocks To Watch Today

By Shanthi Rexaline
November 11, 6:52 AM
Trading in the U.S. index futures points to the buying momentum extending into the final session of the week. The market may turn to the University Of Michigan's consumer sentiment report for trading cues, although profit-taking could take some sheen off the rally.

BABA

Read More

Coya Announces Acceptance Of Oral Presentation, “Regulatory T Cell Expansion Strategy To Target Inflammation In Alzheimer’s Disease: A Phase 1 Feasibility Study,” At The 18th International Conference On Alzheimer’s And Parkinson’s Disease In Lisbon

By Benzinga Newsdesk
October 27, 9:01 AM
Alireza Faridar, MD (Houston Methodist and Weill Cornell Medical College) will present data from an open-label, proof-of-concept study in 8 AD patients treated with Low Dose IL-2 (LD IL-2) over a 4 month period that

COYA